Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5±3°C.


Journal

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
ISSN: 1477-092X
Titre abrégé: J Oncol Pharm Pract
Pays: England
ID NLM: 9511372

Informations de publication

Date de publication:
Sep 2021
Historique:
pubmed: 10 9 2020
medline: 25 11 2021
entrez: 9 9 2020
Statut: ppublish

Résumé

Patients undergoing chemotherapeutic treatment are currently treated by a concomittent infusion of alizapride and ondansetron. To optimise the procedure and to ensure patients' safety, the admixture could be prepared in advance by the Centralized Intravenous Additive Service (CIVAS) provided that the stability of the mixture has been proven beforhand to reduce nausea and vomiting. Five polyolefin bags containing 100 ml sodium chloride 0.9% added with 4 ml alizapride (100 mg) and 4 ml ondansetron (8 mg) were prepared in aseptic conditions and stored at 5 ± 3°C for 56 days. Periodically, physical stability tests were performed including: pH measurements, optical density measurements at 350, 410 and 550 nm to track turbidity appearance, visual and microscopical inspections to detect colour changes, precipitation, microaggregates or crystals. The concentrations of the solutions were measured by High Performance Liquid Chromatography coupled with an UV detector. There was no change in pH and optical densities during the study period. Visual and microscopical inspections didn't show any change of colour neither precipitation, microaggregate or crystal. The alizapride and ondansetron concentrations remained stable over the study. The admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags is physicochemically stable up to 56 days at 5 ± 3°C. These results support the possibility of preparing the solutions in advance by a CIVAS.

Sections du résumé

BACKGROUND BACKGROUND
Patients undergoing chemotherapeutic treatment are currently treated by a concomittent infusion of alizapride and ondansetron. To optimise the procedure and to ensure patients' safety, the admixture could be prepared in advance by the Centralized Intravenous Additive Service (CIVAS) provided that the stability of the mixture has been proven beforhand to reduce nausea and vomiting.
MATERIAL AND METHODS METHODS
Five polyolefin bags containing 100 ml sodium chloride 0.9% added with 4 ml alizapride (100 mg) and 4 ml ondansetron (8 mg) were prepared in aseptic conditions and stored at 5 ± 3°C for 56 days. Periodically, physical stability tests were performed including: pH measurements, optical density measurements at 350, 410 and 550 nm to track turbidity appearance, visual and microscopical inspections to detect colour changes, precipitation, microaggregates or crystals. The concentrations of the solutions were measured by High Performance Liquid Chromatography coupled with an UV detector.
RESULTS RESULTS
There was no change in pH and optical densities during the study period. Visual and microscopical inspections didn't show any change of colour neither precipitation, microaggregate or crystal. The alizapride and ondansetron concentrations remained stable over the study.
CONCLUSION CONCLUSIONS
The admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags is physicochemically stable up to 56 days at 5 ± 3°C. These results support the possibility of preparing the solutions in advance by a CIVAS.

Identifiants

pubmed: 32903143
doi: 10.1177/1078155220950442
doi:

Substances chimiques

Polyenes 0
Pyrrolidines 0
Sodium Chloride 451W47IQ8X
Ondansetron 4AF302ESOS
PL 732 83136-87-2
alizapride P55703ZRZY

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1328-1332

Auteurs

Mélanie Closset (M)

Medical Laboratory, CHU UCL, Namur, Belgium.
Drug Stability Research Group, CHU UCL, Namur, Belgium.

Nicolas Goderniaux (N)

Medical Laboratory, CHU UCL, Namur, Belgium.
Drug Stability Research Group, CHU UCL, Namur, Belgium.

Marie-Lise Colsoul (ML)

Medical Laboratory, CHU UCL, Namur, Belgium.
Drug Stability Research Group, CHU UCL, Namur, Belgium.

Laura Soumoy (L)

Drug Stability Research Group, CHU UCL, Namur, Belgium.
Departement of Pharmacy, CHU UCL, Namur, Belgium.

Benoit Bihin (B)

Drug Stability Research Group, CHU UCL, Namur, Belgium.
Scientific Support Unit, CHU UCL, Namur, Belgium.

Jacques Jamart (J)

Drug Stability Research Group, CHU UCL, Namur, Belgium.
Scientific Support Unit, CHU UCL, Namur, Belgium.

Pascal Odou (P)

GRITA, CHU, Lilles, France.

Jean-Daniel Hecq (JD)

Drug Stability Research Group, CHU UCL, Namur, Belgium.
Departement of Pharmacy, CHU UCL, Namur, Belgium.

Laurence Galanti (L)

Medical Laboratory, CHU UCL, Namur, Belgium.
Drug Stability Research Group, CHU UCL, Namur, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH